CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ACI Global Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ACI Global Corp
16 N Water St # 106
Phone: (203) 987-5356p:203 987-5356 GREENWICH, CT  06830-5834  United States Ticker: ACGJACGJ
This company ceased filing statements with the SEC on 5/2/2003.
Business Summary
ACI Global Corp., formerly Par Advance Technologies Corp., a clinical-stage biopharmaceutical company engaged in the development of natural and novel peptides for the treatment or prevention of infections due to multi-drug resistant bacteria and fungi. The Company's drug candidates are proprietary synthetic and natural peptides (small proteins). Antecedents for these compounds occur in nature as part of the immune system of animals, insects and plants. Generally, the peptides bind to and kill harmful microorganisms and cancer cells. P113D, the Company's product candidate for cystic fibrosis, has been awarded Orphan Drug designation by the United States Food and Drug Administration (FDA). Demegen is also developing a novel, synthetic antimicrobial peptide in a rinse formulation for the treatment and prevention of oral candidiasis. The Company's peptide technology can also be used to prevent serious damage to crops caused by fungal and bacterial diseases.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20029/30/2002YesYes---

Industries
SIC Code Description
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Financial Officer, Secretary Richard D.Ekstrom 64 12/1/2001 12/1/1994
Director Joseph F.Lovett 7/23/2001 7/23/2001

Business Names
Business Name
ACGJ
ACI Global Corporation
Demegen, Inc.
Par Advance Technologies Corp

General Information
Number of Employees: 3 (As of 9/30/2002)
Outstanding Shares: 47,367,778 (As of 2/7/2003)
Shareholders: 503
Stock Exchange: OTC
Federal Tax Id: 841065575
Fax Number: (412) 244-12161
Email Address: info@demegen.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023